Generic Drug Prices Should Be 50% Of Originator: Japan’s MHLW
This article was originally published in PharmAsia News
Japan’s MHLW has submitted a proposal to the Central Social Insurance Medical Council’s Committee on Drug Price suggesting that the price of generic drugs to be added to the NHI price listing should be 50% of the price of originator drugs.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.